Alcobra Ltd. is an emerging biopharmaceutical company that develops and markets drugs for the treatment of central nervous system disorders and cognitive dysfunctions. The company is primarily focused on developing and marketing its most advanced drug, MG01CI, a non-stimulant attention deficit hyperactivity disorder drug for adults and children, which has completed phase II clinical trial studies. For more information, visit the company’s website at www.alcobra-pharma.com.